ISSN:
1582-1838
eISSN:
1582-4934
Disciplines
(Field of Science):
- biomedical engineering (Engineering and Technology)
- medical biology (Medical and Health Sciences )
- pharmacology and pharmacy (Medical and Health Sciences )
- medical sciences (Medical and Health Sciences )
- health sciences (Medical and Health Sciences )
- biotechnology (Natural sciences)
- biological sciences (Natural sciences)
- chemical sciences (Natural sciences)
(Field of Science)
Ministry points: Help
Year | Points | List |
---|---|---|
Year 2024 | 100 | Ministry scored journals list 2024 |
Year | Points | List |
---|---|---|
2024 | 100 | Ministry scored journals list 2024 |
2023 | 100 | Ministry Scored Journals List |
2022 | 100 | Ministry Scored Journals List 2019-2022 |
2021 | 100 | Ministry Scored Journals List 2019-2022 |
2020 | 100 | Ministry Scored Journals List 2019-2022 |
2019 | 100 | Ministry Scored Journals List 2019-2022 |
2018 | 35 | A |
2017 | 35 | A |
2014 | 10 | B |
2013 | 35 | A |
2012 | 35 | A |
2011 | 35 | A |
2010 | 32 | A |
Model:
Open Access
Points CiteScore:
Year | Points |
---|---|
Year 2023 | 11.5 |
Year | Points |
---|---|
2023 | 11.5 |
2022 | 10 |
2021 | 7.6 |
2020 | 5.9 |
2019 | 5.6 |
2018 | 6.1 |
2017 | 7.7 |
2016 | 8.1 |
2015 | 7.7 |
2014 | 8.1 |
2013 | 8.5 |
2012 | 8.4 |
2011 | 7.8 |
Impact Factor:
Log in to see the Impact Factor.
Sherpa Romeo:
Papers published in journal
Filters
total: 1
Catalog Journals
Year 2022
-
Combined anticancer therapy with imidazoacridinone analogue C‐1305 and paclitaxel in human lung and colon cancer xenografts—Modulation of tumour angiogenesis
PublicationThe acridanone derivative 5-dimethylaminopropylamino- 8- hydroxytriazoloacridinone (C-1305) has been described as a potent inhibitor of cancer cell growth. Its mechanism of action in in vitro conditions was attributed, among others, to its ability to bind and stabilize the microtubule network and subsequently exhibit its tumour- suppressive effects in synergy with paclitaxel (PTX). Therefore, the objective of the present study...
seen 670 times